Imaging Test Targeting DLL3 Protein in Neuroendocrine Carcinoma
Compares a DLL3-targeted PET scan with standard imaging in neuroendocrine carcinoma patients.
Plain-language title generated from the registry record
Registry title: DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Key facts
- Where
- Xiamen, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07458906, who can take part
Where in China
- The First Affiliated hospital of Xiamen UniversityXiamen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Xiamen University
- Trial code
- NCT07458906
- Record updated
- 25 September 2026
- Original description
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.Read full original descriptionShow less
Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
Inclusion: Adult patients (aged 18 years or older); Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report); Serum ProGRP or NSE level ≥ 3 times the upper limit of normal; Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee; Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits.
Exclusion: The inability or unwillingness of the research participant or legal representative to provide written informed consent; Inability to complete PET/CT imaging.